These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 29882302

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Anticancer drug development from traditional cytotoxic to targeted therapies: evidence of shorter drug research and development time, and shorter drug lag in Japan.
    Kawabata-Shoda E, Masuda S, Kimura H.
    J Clin Pharm Ther; 2012 Oct; 37(5):547-52. PubMed ID: 22428857
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
    Yamashita K, Kaneko M, Narukawa M.
    Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
    [Abstract] [Full Text] [Related]

  • 6. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
    Maeda H, Kurokawa T.
    Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
    Maeda H, Kurokawa T.
    J Clin Pharmacol; 2015 May; 55(5):481-9. PubMed ID: 25560978
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Safety-Related Regulatory Actions and Risk Factors for Anticancer Drugs in Japan.
    Nakayama H, Matsumaru N, Tsukamoto K.
    Pharmaceut Med; 2019 Feb; 33(1):45-52. PubMed ID: 31933266
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.
    Zhou L, Higashimori M, Shen K, Zhang Z, Sheng J, Xu H, Horiuchi M, Ichikawa K, Al-Huniti N, Zhou D.
    Clin Pharmacol Ther; 2019 Jun; 105(6):1303-1320. PubMed ID: 30802932
    [No Abstract] [Full Text] [Related]

  • 15. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan.
    Hino Y, Okada M, Hallgreen CE, De Bruin ML, Doty RE, Matsumaru N, Tsukamoto K.
    Biol Pharm Bull; 2023 May 01; 46(5):700-706. PubMed ID: 36878610
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Performing phase I clinical trials of anticancer agents: perspectives from within the European union and Japan.
    Forster MD, Saijo N, Seymour L, Calvert H.
    Clin Cancer Res; 2010 Mar 15; 16(6):1737-44. PubMed ID: 20215555
    [Abstract] [Full Text] [Related]

  • 18. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E, Kaneko M, Narukawa M.
    Ther Innov Regul Sci; 2021 Mar 15; 55(2):336-345. PubMed ID: 32959206
    [Abstract] [Full Text] [Related]

  • 19. Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.
    Barone A, Casey D, McKee AE, Reaman G.
    Pediatr Blood Cancer; 2019 Aug 15; 66(8):e27809. PubMed ID: 31144772
    [Abstract] [Full Text] [Related]

  • 20. Differences between Japan and the United States in dosages of drugs recently approved in Japan.
    Nakashima K, Narukawa M, Kanazu Y, Takeuchi M.
    J Clin Pharmacol; 2011 Apr 15; 51(4):549-60. PubMed ID: 20628171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.